SINGAPORE, Nov. 1, 2022 /PRNewswire/ GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supported Chulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production and characterization services. The antibodies were licensed to Hibiocy Co. Ltd., which further developed them into a nasal spray medical device named VAILL COVITRAP. The Thai FDA has approved VAILL COVITRAP as a Class 4 medical device, making Thailand the first country to approve the manufacturing of human monoclonal antibody-based COVID-19 nasal spray. The human anti-SARS-CoV-2 antibodies which area crucial part ofthe VAILL COVITRAP nasal spray device weredeveloped by Dr. Trairak Pisitkun's team from Chulalongkorn University, Bangkok, Thailand. GenScript has supported the team with antibody production and characterization during the early phase of research and contributed to the d